

The Chronic Lymphocytic Leukemia Foundation has awarded a grant to Dr. Steven Kornblau of the University of Texas MD Anderson Cancer Center. Dr. Kornblau will undertake a proteomics study of CLL and related B-Cell leukemias and lymphomas to determine the protein expression signatures of the disease. His study will analyze numerous tissue samples from patients with the help of the Reverse Phase Protein Array technology available at MD Anderson. This cutting edge technology will enable Dr. Kornblau to determine the proteins expressed by the CLL and related disease cells. This information should be useful for understanding the causes, progression, and treatment of chronic lymphocytic leukemia.